<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385877</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00088601</org_study_id>
    <nct_id>NCT02385877</nct_id>
  </id_info>
  <brief_title>Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines</brief_title>
  <official_title>Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines for Quantification of Regional Cardiac Sympathetic Nerve Density With PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac&#xD;
      sympathetic nerve imaging agents, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG)&#xD;
      and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, PET imaging studies of two structurally related&#xD;
      18F-hydroxyphenethylguanidines, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG)&#xD;
      and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) will be performed. All&#xD;
      studies will be performed in normal healthy volunteers.&#xD;
&#xD;
      PET stands for Positron Emission Tomography which is a type of imaging that uses a&#xD;
      radioactive tracer. This is also called a radiotracer which is a compound linked to a&#xD;
      radioactive element. Most compounds are short-lived, meaning that the radioactivity breaks&#xD;
      down quickly or is excreted from the body.&#xD;
&#xD;
      In the first stage of the study, dynamic PET imaging for 90 min will be done with&#xD;
      [18F]4F-MHPG (n = 4) and [18F]3F-PHPG (n = 4).&#xD;
&#xD;
      Data from these studies will assess each radiotracer's imaging properties, pharmacokinetics&#xD;
      and metabolic breakdown in plasma. Application of tracer kinetic analysis methods to the&#xD;
      kinetics of each tracer in heart and plasma will be studied to see if these methods can&#xD;
      provide accurate measurements of regional nerve sympathetic nerve density in the hearts of&#xD;
      human subjects. Results from these initial studies will be used to select the lead compound&#xD;
      for further studies in patient populations.&#xD;
&#xD;
      In the second stage of the study, whole-body PET imaging studies (n = 4) with the selected&#xD;
      lead radiotracer will be performed to acquire data necessary for generating more accurate&#xD;
      human radiation absorbed dose estimates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite measure based on radiotracer tissue uptake ratios (heart-to-lung ratio, heart-to-liver ratio, heart-to-blood ratio) and rates of metabolism in plasma (half-time, in minutes) of [18F]4F-MHPG and [18F]3F-PHPG in healthy subjects.</measure>
    <time_frame>3 months</time_frame>
    <description>These data will be used to select the lead radiotracer for further clinical development.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiation Dose</measure>
    <time_frame>1 year</time_frame>
    <description>Human radiation absorbed dose estimates based on the kinetics of the selected lead radiotracer in various organs, as extracted from whole-body PET scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Number of study participants with adverse events as a measure of safety and tolerability following intravenous administration of [18F]4F-MHPG or [18F]3F-PHPG</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Autonomic Peripheral Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Protocol 1: [18F]4F-MHPG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (n = 4) will be injected one time with 6.5 mCi of 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and receive a 90 minute PET scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol 1: [18F]3F-PHPG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (n = 4) will be injected one time with 6.5 mCi of 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) and receive a 90 minute PET scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol 2: Biodistribution Studies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (n = 4) will be injected one time with 6.5 mCi of either [18F]4F-MHPG or [18F]3F-PHPG (whichever is selected based on Protocol 1 studies) and receive four whole-body PET scans, starting at 5 min, 60 min, 150 min and 360 min after tracer injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]4F-MHPG</intervention_name>
    <description>IV injection of [18F]4F-MHPG</description>
    <arm_group_label>Protocol 1: [18F]4F-MHPG</arm_group_label>
    <arm_group_label>Protocol 2: Biodistribution Studies</arm_group_label>
    <other_name>4-[18F]fluoro-meta-hydroxyphenethylguanidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]3F-PHPG</intervention_name>
    <description>IV injection of [18F]3F-PHPG</description>
    <arm_group_label>Protocol 1: [18F]3F-PHPG</arm_group_label>
    <arm_group_label>Protocol 2: Biodistribution Studies</arm_group_label>
    <other_name>3-[18F]fluoro-para-hydroxyphenethylguanidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-obese (BMI &lt; 30)&#xD;
&#xD;
          -  Normal blood pressure&#xD;
&#xD;
          -  Normal blood lipid profile&#xD;
&#xD;
          -  No history of prior cardiovascular disease&#xD;
&#xD;
          -  Not susceptible to claustrophobia&#xD;
&#xD;
          -  Ability to lay flat for 90 min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obesity (BMI &gt; 30)&#xD;
&#xD;
          -  Risk factors for heart disease (age &gt; 55y, hypertension, smoking, high blood pressure,&#xD;
             high cholesterol levels, diabetes, etc.)&#xD;
&#xD;
          -  History of heart disease (heart attack, atrial fibrillation, ventricular tachycardia,&#xD;
             exertional angina)&#xD;
&#xD;
          -  Currently using certain medications that may interact with cardiac nerves&#xD;
             (antidepressants, cold medications, nasal decongestants, monoamine oxidase inhibitors,&#xD;
             etc.)&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Inability to lie flat for 90 min&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Raffel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>David M. Raffel, Ph.D.</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

